Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients: Results from a real-life patient cohort

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with a high mortality. To date no trial comparing hydroxychloroquine (HCQ) and lopinavir/ritonavir (LPV/RTV) has been performed. METHODS: Hospitalized patients ≥18 years old with severe coronavirus disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Karolyi, Mario, Pawelka, Erich, Mader, Theresa, Omid, Sara, Kelani, Hasan, Ely, Sarah, Jilma, Bernd, Baumgartner, Sebastian, Laferl, Hermann, Ott, Clemens, Traugott, Marianna, Turner, Michael, Seitz, Tamara, Wenisch, Christoph, Zoufaly, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2020
Materias:
Main Topic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416584/
https://www.ncbi.nlm.nih.gov/pubmed/32776298
http://dx.doi.org/10.1007/s00508-020-01720-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416584/
https://www.ncbi.nlm.nih.gov/pubmed/32776298
http://dx.doi.org/10.1007/s00508-020-01720-y

Ejemplares similares